Stock of the day: Pro Medicus
Discover why Pro Medicus (ASX: PME) is captivating investors with a record-breaking $330 million contract, strong momentum, and analyst upgrades despite valuation concerns.
(AI video summary)
This video was created on 4 December for IG audiences by ausbiz.
ASX code: PME
Insider moves and analyst upgrades
Pro Medicus continues to capture market attention, following news that its co-founders, Dr Sam Hupert and Anthony Hall, do not plan to sell additional shares in the foreseeable future. This announcement comes after the co-founders each sold 1 million Pro Medicus shares, representing 4% of their holdings, in a regular six-month pattern.
Adding to the excitement, Bell Potter upgraded its price target for Pro Medicus by almost 100%, now valuing the stock at $260. Despite the upgrade, the stock has already surpassed this level, reflecting strong market confidence. Bell Potter's analysts acknowledged their previous underestimation of the company's value, highlighting significant contract upgrades and market leadership as key drivers.
Record-breaking contracts
Pro Medicus recently signed a landmark 10-year, $330 million contract with one of the largest hospital systems in the United States. This deal follows a trend of exponentially growing contracts, reflecting the company’s success in transitioning from academic hospitals to larger public systems.
While Morgans raised its price target to $225, well below the current share price, the firm described the latest contract as 'shockingly large,' underscoring Pro Medicus’ ability to secure significant deals.
A high-quality yet expensive stock
According to Michael, a portfolio manager and long-time holder of Pro Medicus, the company remains a high-quality business with impressive growth figures such as revenues up 30% – 40%, and earnings are climbing at a similar pace. However, he admits that the valuation seems extreme, with a price-to-earnings (P/E) ratio far above historical norms.
Michael shared that Pro Medicus has historically provided opportunities for investors to buy during pullbacks of 30% – 50%, but recent performance has made such corrections rare. While he holds a 'hold' rating on the stock, he recommends waiting for a significant weakness before adding more.
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Explore the markets with our free course
Discover the range of markets you can trade CFDs on - and learn how they work - with IG Academy's online course.
Turn knowledge into success
Practice makes perfect. Take what you’ve learned in this shares strategy article, and try it out in your demo account.
Ready to trade shares?
Put the lessons in this article to use in a live account. Upgrading is quick and simple.
- Trade over 13,000 popular global stocks
- Protect your capital with risk management tools
- Deal on 70 key US stocks out-of-hours, so you can react to news
Inspired to trade?
Put the knowledge you’ve gained from this article into practice. Log in to your account now.
Live prices on most popular markets
- Forex
- Shares
- Indices
